TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24025983
Drug: Mericitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mericitabine 1000 mg
Study: 24025983
Drug: Mericitabine 2000
Normalized name: gemcitabine 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mericitabine 2000 mg
Study: 24025983
Drug: Mericitabine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mericitabine (all doses)
Study: 10897159
Drug: LEV 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 1,000 mg
Study: 15679515
Drug: LEV 333
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Uni-Lev 5.0]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 333 mg
Study: 2669119
Drug: Omeprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (30 mg)
Study: 2669119
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g)
Study: 353659
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin (t.i.d.)
Study: 353659
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin (t.i.d.) combined with aspirin
Study: 11802037
Drug: Intranasal azelastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal azelastine
Study: 23834132
Drug: Isotonic sea
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sea water nasal spray
Study: 9360699
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of fibrin glue added to peritoneal cuff suture
Study: 2886245
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine
Study: 1544289
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg quinidine
Study: 4054204
Drug: Cianergoline (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cianergoline (maximum daily dose 12 +/- 2 mg for 4 weeks)
Study: 30269640
Drug: Automated telemedicine
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated telemedicine intervention (daily phone messages with proactive alerts)
Study: 30269640
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily phone messages without proactive alerts)
Study: 29914666
Drug: 800 mg/d
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/d resveratrol for 8 weeks
Study: 22994055
Drug: Compound Xuanju
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Xuanju Capsule
Study: 22994055
Drug: Antibiotics (Control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (Control)
Study: 16293868
Drug: Single-agent gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent gemcitabine (G arm)
Study: 396055
Drug: Praziquantel 3
Normalized name: praziquantel 34 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 3 x 20 mg/kg
Study: 396056
Drug: Praziquantel 1
Normalized name: praziquantel 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 1 x 50 mg/kg
Study: 30948756
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg L-DOPA (low-weight participants)
Study: 30265586
Drug: Early diagnosis
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early diagnosis and treatment of glucocorticoid-induced adverse events
Study: 28069040
Drug: Acupuncture, electroacupuncture,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture, electroacupuncture, and intradermal acupuncture (6 sessions within 8 days starting within 48 hours of craniotomy)
Study: 25886483
Drug: Acupuncture, electroacupuncture,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture, electroacupuncture, and intradermal acupuncture
Study: 21893447
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg/d) for six weeks
Study: 12623744
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg) and selenium (225 microg) supplementation for 3 months
Study: 12623744
Drug: Vitamin B
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B (4.5 g/day) for 3 months
Study: 15096005
Drug: Intravenous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous therapy with continuous IGF‐I (0.01 mg/kg/hour)
Study: 8437596
Drug: High-dose carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose carboplatin alone (800 mg per square meter)
Study: 26919410
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg s.c. at baseline, week 1, 2, 3, and 4, then every 4 weeks (with up-titration to 300 mg for 2 non-responders)
Study: 20231321
Drug: No-dose-reduction group
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-dose-reduction group (initial optimal therapeutic dose continued throughout the study)
Study: 20231321
Drug: 4-week group
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week group (initial optimal therapeutic dose continued for 4 weeks, followed by a 50% dose reduction)
Study: 20231321
Drug: 26-week group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26-week group (initial optimal therapeutic dose continued for 26 weeks, followed by a 50% dose reduction)
Study: 18341673
Drug: Brivaracetam 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 800 mg/day
Study: 10606361
Drug: Synacthen depot
Normalized name: Synacthen Depot
DrugBank: Tetracosactide (DB01284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synacthen depot 0.5 mg on alternate days for 2 injections
Study: 2840279
Drug: Guar biscuit
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar biscuit (2.9 g of guar)
Study: 2840279
Drug: Guar biscuit
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar biscuit (6.0 g of guar)
Study: 2840279
Drug: Guar biscuit
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar biscuit (9.1 g of guar)
Study: 21878067
Drug: Coenzyme Q(10)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme Q(10) in combination with enalapril
Study: 15478524
Drug: Midodrine 10
Normalized name: midodrine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine 10 mg
Study: 9674789
Drug: Midodrine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine 20 mg
Study: 9674789
Drug: Midodrine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (2.5, 10, or 20 mg)
Study: 8072201
Drug: Neoadjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant endocrine therapy followed by surgery
Study: 8072201
Drug: Neoadjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant endocrine therapy followed by irradiation
Study: 12525260
Drug: Maca 1500
Normalized name: MACA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maca 1500 mg
Study: 12525260
Drug: Maca 3000
Normalized name: MACA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maca 3000 mg
Study: 26355167
Drug: 4.0 mm-long
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mm-long implants
Study: 27990507
Drug: 10 mm
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mm or longer implants in augmented bone
Study: 27990507
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants (4.0 mm)
Study: 27990507
Drug: 10 mm
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mm or longer mandibular implants
Study: 25738177
Drug: Short maxillary
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short maxillary implants
Study: 27990507
Drug: 10 mm
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mm or longer maxillary implants
Study: 27990507
Drug: Augmented group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented group (10 mm or longer implants)
Study: 23327881
Drug: Tacrolimus (Tac)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (Tac) administered once daily at a dose of 3 mg
Study: 11823664
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (biweekly intravenous alpha-galactosidase A infusions)
Study: 10369625
Drug: Once-daily aminoglycosides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily aminoglycosides (ODA)
Study: 10369625
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing of aminoglycosides
Study: 7771004
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 monotherapy (20 micrograms)
Study: 7771004
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Prostaglandin E1 20 micrograms plus lidocaine 1% 1 cc)
Study: 2335312
Drug: Induction with
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction with oxytocin infusion
Study: 24445833
Drug: Inactivated quadrivalent
Normalized name: influenza virus vaccine, inactivated quadrivalent intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated quadrivalent influenza vaccine (QIV)
Study: 26336604
Drug: Trivalent control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent control vaccine (TIV)
Study: 8615362
Drug: High-resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-resistant starch (39 +/- 3 g/d)
Study: 8615362
Drug: Low-resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-resistant starch (5 +/- 0.4 g/d)
Study: 1351126
Drug: HDC (6.52
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDC (6.52 international potency units per dose)
Study: 3969876
Drug: Bretylium 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bretylium 2.5 mg/kg over 60 minutes
Study: 3969876
Drug: Bretylium 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bretylium 5.0 mg/kg over 60 minutes
Study: 3969876
Drug: Bretylium 10
Normalized name: bretylium 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bretylium 10 mg/kg over 60 minutes
Study: 24690964
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (2.5 g per day of eicosapentaenoic + docosahexaenoic)
Study: 17661245
Drug: Morning preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning preparation
Study: 17661245
Drug: Evening preparation
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening preparation
Study: 16128276
Drug: Genetically derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically derived vaccine (20 microg)
Study: 16128276
Drug: Plasma pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma pooled vaccine (3 microg)
Study: 9846796
Drug: Chlorhexidine (0.12%)
Normalized name: chlorhexidine 12 MG
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (0.12%) and Perborate (1.9 g sodium perborate-monohydrate in 30 ml water)
Study: 8003060
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus probenecid for 30 days
Study: 2553364
Drug: UFTM (UFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFTM (UFT and mitomycin C); UFT: 30 g total dose, Mitomycin C: 48-60 mg total dose
Study: 30650418
Drug: Early palliative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early palliative care intervention (monthly intervention by palliative care specialists at home for 12 months)
Study: 21859900
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (AC) with gemcitabine 1000 mg/m² on days 1, 8, and 15 and cisplatin 70 mg/m² on day 2, every 28 days.
Study: 21859900
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (AC) with gemcitabine and cisplatin as above.
Study: 21859900
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (AC) with cisplatin on day 2.
Study: 11473839
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine (6 to 10 mL of 0.25% bupivacaine epidurally, followed by infusion at 3 to 5 mL/h for 3 days)
Study: 11473839
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (2 to 3 mg morphine epidurally, followed by infusion at a rate of 0.2 mg/h)
Study: 9892913
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine 250 mg once daily for 1 week
Study: 9892913
Drug: 1% clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clotrimazole cream applied twice daily for 4 weeks
Study: 3291529
Drug: CQP 201‐403
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQP 201‐403 at 0.005 mg daily
Study: 3291529
Drug: CQP 201‐403
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQP 201‐403 at 0.015 mg daily
Study: 3291529
Drug: CQP 201‐403
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQP 201‐403 at 0.025 mg daily
Study: 1711753
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of bleomycin sulphate (1 unit/ml)
Study: 28965748
Drug: Pharmacist case
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist case finding and intervention program (Medication Therapy Management consultation, patient assessment, laboratory assessment, individualized CV risk assessment)
Study: 15142088
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with immediate implant and subepithelial connective tissue graft (test group)
Study: 15142088
Drug: Single immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single immediate implants (control group)
Study: 9882085
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen trometamol 25 mg tid
Study: 9882085
Drug: Ketoprofen 50
Normalized name: ketoprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 50 mg tid
Study: 8049819
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg terbutaline
Study: 2893778
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg terbutaline
Study: 1813613
Drug: Desipramine (tricyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (tricyclic antidepressant)
Study: 2500111
Drug: Fluvoxamine (5-HT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (5-HT reuptake inhibitor)
Study: 26939522
Drug: Cer‐Mg and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cer‐Mg and hydrocortisone
Study: 26939522
Drug: Cer‐Mg and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cer‐Mg and emollient
Study: 26939522
Drug: Cer‐Mg cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cer‐Mg cream
Study: 23136274
Drug: Diagnostic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic and treatment package for malaria and pneumonia using rapid diagnostic tests (RDT)
Study: 23136274
Drug: Presumptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presumptive treatment with anti-malarial drugs; artemisinin combination therapy (ACT)
Study: 15302228
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg beta‐methyl‐6‐chloromelatonin
Study: 15302228
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg beta‐methyl‐6‐chloromelatonin
Study: 15302228
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg beta‐methyl‐6‐chloromelatonin
Study: 1353678
Drug: Vecuronium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.5 mg bolus i.v. followed by 0.5 mg infused over 30 min)
Study: 25407798
Drug: Aleglitazar 150
Normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleglitazar 150 μg/day
Study: 21995889
Drug: Life review
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life review therapy
Study: 22420349
Drug: Placebo condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo condition with supportive therapy
Study: 17563512
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of mandibular bar-retained overdenture supported by 4 endosseous implants loaded immediately after implant placement.
Study: 17563512
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of mandibular bar-retained overdenture supported by 4 endosseous implants that remained submerged for a period of 4 months before loading.
Study: 12182268
Drug: Cue exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cue exposure following a priming dose
Study: 15753142
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplements
Study: 7015820
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplements
Study: 2182978
Drug: Active management
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active management with i.v. Ergometrine 0.5 mg
Study: 15377842
Drug: Intravenous clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clodronate (1500 mg each, seven cycles)
Study: 11429351
Drug: Morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1 mg/mL plus ketamine 1 mg/mL (Group MK)
Study: 11429351
Drug: Morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1 mg/mL (Group M)
Study: 9701181
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (375 mL/d)
Study: 9701181
Drug: RWPP capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWPP capsules (1 g/d)
Study: 9701181
Drug: RWPPs in
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWPPs in white wine (1 g/d)
Study: 9701181
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine (375 mL/d)
Study: 9701181
Drug: Control alcoholic
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control alcoholic drink (40 g ethanol/d)
Study: 9701181
Drug: RWPPs (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWPPs (1 g/d)
Study: 9701181
Drug: RWPPs (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWPPs (2 g/d)
Study: 9390335
Drug: Tacalcitol ointment
Normalized name: tacalcitol
DrugBank: Tacalcitol (DB13689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacalcitol ointment (4 micrograms/g) once daily
Study: 9390335
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment (50 micrograms/g) twice daily
Study: 1759492
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (PT‐9K/129G, FHA, 69 kDa)
Study: 7117678
Drug: Nabumetone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (1 g at night) for 2 weeks
Study: 7117678
Drug: Naproxen (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (250 mg b.i.d) for 2 weeks
Study: 7117678
Drug: Drug preference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug preference
Study: 31605520
Drug: Caffeine tablet
Normalized name: Caffeine Tablets
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine tablet (CT)
Study: 15462108
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 mg once daily)
Study: 15462108
Drug: Fosinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (20 mg once daily)
Study: 3943269
Drug: Nalmefene 2
Normalized name: nalmefene 27 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 2 mg
Study: 3946804
Drug: Nalmefene 1
Normalized name: nalmefene 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 1 mg
Study: 3946804
Drug: Nalmefene 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 0.5 mg
Study: 27085566
Drug: Oximacro (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oximacro (36 mg PACs‐A) administered twice per day for 7 days
Study: 27085566
Drug: Oximacro (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oximacro (36 mg PACs‐A)
Study: 24399428
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus clonazepam (up to 3.0 mg/day)
Study: 24399428
Drug: Venlafaxine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (up to 225 mg/day)
Study: 18417963
Drug: Danqi Piantan
Normalized name: Yellow fever virus 17D/tiantan live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danqi Piantan Jiaonang (DPJ) 4 capsules (0.4 g/capsule) taken orally 2 times 6 hours apart
Study: 18417963
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin 300 mg and 2 doses of DPJ 4 capsules taken 6 hours apart
Study: 18417963
Drug: Danqi Piantan
Normalized name: Yellow fever virus 17D/tiantan live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danqi Piantan Jiaonang (DPJ) 4 capsules taken orally 3 times a day for 1 month
Study: 15783004
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no herbal medicine)
Study: 30167807
Drug: Intensive systolic
Normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive systolic blood pressure treatment (< 120 mmHg) in the low-SBP group
Study: 30167807
Drug: Standard systolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systolic blood pressure treatment (< 140 mmHg) in the low-SBP group